JP2024534602A5 - - Google Patents
Info
- Publication number
- JP2024534602A5 JP2024534602A5 JP2024518659A JP2024518659A JP2024534602A5 JP 2024534602 A5 JP2024534602 A5 JP 2024534602A5 JP 2024518659 A JP2024518659 A JP 2024518659A JP 2024518659 A JP2024518659 A JP 2024518659A JP 2024534602 A5 JP2024534602 A5 JP 2024534602A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- subject
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247637P | 2021-09-23 | 2021-09-23 | |
| US63/247,637 | 2021-09-23 | ||
| PCT/US2022/076694 WO2023049694A1 (en) | 2021-09-23 | 2022-09-20 | Methods of treating multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534602A JP2024534602A (ja) | 2024-09-20 |
| JP2024534602A5 true JP2024534602A5 (enExample) | 2025-09-22 |
Family
ID=83996580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518659A Pending JP2024534602A (ja) | 2021-09-23 | 2022-09-20 | 多発性骨髄腫を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240343819A1 (enExample) |
| EP (1) | EP4405393A1 (enExample) |
| JP (1) | JP2024534602A (enExample) |
| CA (1) | CA3232799A1 (enExample) |
| TW (1) | TW202327650A (enExample) |
| WO (1) | WO2023049694A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12667555B2 (en) | 2022-05-20 | 2026-06-30 | Springworks Therapeutics, Inc. | Treatment of ovarian cancer with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| AU2024390850A1 (en) * | 2023-12-01 | 2026-04-02 | Teneoone, Inc. | Methods for the treatment of multiple myeloma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| AU2005290250A1 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| MX2012002651A (es) | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| MA44254A (fr) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques |
| MX2021012407A (es) * | 2019-04-10 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa. |
-
2022
- 2022-09-19 TW TW111135302A patent/TW202327650A/zh unknown
- 2022-09-20 CA CA3232799A patent/CA3232799A1/en active Pending
- 2022-09-20 EP EP22797206.4A patent/EP4405393A1/en active Pending
- 2022-09-20 US US18/694,483 patent/US20240343819A1/en active Pending
- 2022-09-20 JP JP2024518659A patent/JP2024534602A/ja active Pending
- 2022-09-20 WO PCT/US2022/076694 patent/WO2023049694A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2023544407A5 (enExample) | ||
| JP2023520771A5 (enExample) | ||
| JP7160533B2 (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP2023524149A5 (enExample) | ||
| JP2023505218A5 (enExample) | ||
| JP2023542290A5 (enExample) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021512107A5 (enExample) | ||
| US20250075007A1 (en) | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | |
| KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| JP2024540435A5 (enExample) | ||
| JP2022513029A5 (enExample) | ||
| JP2023537078A5 (enExample) | ||
| JP2025509567A5 (enExample) | ||
| JP2024528877A5 (enExample) | ||
| TW202321303A (zh) | 抗pla2r自體抗體媒介膜性腎病變之治療 | |
| JP2023546504A5 (enExample) | ||
| JP2023506779A5 (enExample) | ||
| JP2022521773A5 (enExample) | ||
| JP2022520572A5 (enExample) | ||
| JP2023550311A5 (enExample) | ||
| JP2024526742A5 (enExample) | ||
| JP2025503176A5 (enExample) | ||
| JP2022553378A5 (enExample) |